KPTI

Business Context and Reporting Period

Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company focused on the development and commercialization of XPO1 inhibitors, primarily its lead asset XPOVIO (selinexor) for the treatment of multiple myeloma and other cancers. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single segment and is currently classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Total Debt Obligations include the Senior Secured Term Loan ($124.6M), New 2029 Notes ($108.0M), and 2028 Notes ($15.6M).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 17% year-over-year, driven primarily by a 39% increase in net product revenue to $29.2 million. This growth was attributed to lower gross-to-net discounts and a reduction in product return reserves compared to an unusually high reserve recorded in Q1 2025.
• License Revenue Decline: License and other revenue decreased 34% to $5.9 million, largely due to the expiration of a $7.0 million reimbursement obligation from partner Menarini in the prior year. This was partially offset by a $3.5 million milestone payment from a privately-held biotech partner.
• Operating Expenses: Total operating expenses decreased slightly by 2% to $61.8 million. Research and Development (R&D) expenses remained relatively flat at $33.8 million, while Selling, General, and Administrative (SG&A) expenses decreased to $26.7 million.
• Liquidity Improvement: Cash and cash equivalents increased significantly from $60.5 million at year-end 2025 to $90.9 million at March 31, 2026, following equity financing activities.

Guidance, Outlook, Risks, and Unusual Items

Going Concern Warning

Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern within one year of the filing date. This assessment is based on recurring operating losses, significant debt service obligations, and the uncertainty of securing additional funding. The company expects its current liquidity to fund operations only through late Q3 2026.

Clinical and Regulatory Updates

• SENTRY Trial (Myelofibrosis): Announced topline data in March 2026. The trial met its first co-primary endpoint (spleen volume reduction) but failed to meet the second (symptom score). Management plans to engage the FDA regarding a supplemental New Drug Application (sNDA).
• DLBCL Indication: The company voluntarily withdrew the accelerated approval for Diffuse Large B-Cell Lymphoma (DLBCL) in March 2026 due to the infeasibility of completing the required confirmatory trial.
• Upcoming Data: Topline data for the Phase 3 XPORT-EC-042 trial (endometrial cancer) is expected in mid-2026, and the EMN29 trial (multiple myeloma) in late 2026.

Debt and Financing

• Recent Capital Raise: In March 2026, the company raised approximately $46.7 million in net proceeds through a private placement ($26.9 million) and an Open Market Sale Agreement ($19.8 million).
• Debt Restructuring: The company entered into a Forbearance Agreement in March 2026 with lenders and noteholders, allowing for the deferral of certain interest payments until September 2026 and aligning liquidity covenants.
• Interest Expense: Interest expense increased to $12.6 million due to higher rates on the senior secured term loan and convertible debt, though a portion of interest is currently payable in-kind.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to raise additional capital before late Q3 2026 to avoid liquidity crises or forced asset sales.
• Debt Covenants: Monitor compliance with the Minimum Liquidity Covenant (currently $10M + 50% of proceeds, capped at $25M) and the impact of the Forbearance Agreement expiration.
• Regulatory Pathway: Assess the FDA's response to the SENTRY trial data and the likelihood of approval for the myelofibrosis indication given the mixed results.
• Revenue Sustainability: Evaluate the sustainability of product revenue growth given the expiration of partner reimbursement revenues and the competitive landscape in multiple myeloma.
• Dilution Risk: Review the impact of outstanding warrants (over 14 million shares) and convertible notes on future share count and earnings per share.